Consensus on the appropriate use of intrathecal baclofen (ITB) therapy in paediatric spasticity

Bernard Dan*, Francesco Motta, Johann S. H. Vles, Michael Vloeberghs, Jules G. Becher, Paul Eunson, Vincent Gautheron, Sonnhild Luetjen, Volker Mall, Samuel Ignacio Pascual-Pascual, Petra Pauwels, Geir Ketil Roste

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Among features of motor disorders in children, spasticity is associated with considerable morbidity and problems in care, particularly in severely affected patients. Intrathecal baclofen (ITB) has been increasingly used as a relatively specific treatment modality for spasticity. To date, most of the evidence for its use in paediatric patients has come from retrospective and uncontrolled studies, although randomised, controlled trials of screening ITB and ITB therapy itself have recently been published. This consensus statement on the use of ITB in paediatric patients with spasticity was developed on the basis of currently available evidence, with the aim of providing information for clinicians, promoting an expert opinion and a consistent approach to the management of these patients and emphasising the need for further prospective, large-scale studies.
Original languageEnglish
Pages (from-to)19-28
JournalEuropean Journal of Paediatric Neurology
Issue number1
Publication statusPublished - Jan 2010


  • Intrathecal baclofen
  • Paediatric
  • Spasticity
  • Treatment

Cite this